The National Security Agency in France and the Federal Agency for Medicines and Health Products in Belgium have granted regulatory approvals to Theravectys to initiate a Phase I/II clinical trial of its anti-HIV therapeutic vaccine.

The anti-HIV vaccine uses the biotechnology company’s lentiviral vector technology to induce the cellular immune system for the removal of infected cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The double-blind, controlled, placebo study will enrol 36 patients from four clinical centres in France and two in Belgium, to assess the safety and tolerance of the vaccine and measure the quality and intensity of the induced immune response.

"The anti-HIV vaccine uses the biotechnology company’s lentiviral vector technology to induce the cellular immune system for the removal of infected cells."

The vaccine is being developed with the intention of stopping patients taking antiretroviral drugs on a sustainable basis after the treatment.

Cochin-Pasteur Clinical Investigation Center coordinator and coordinating investigator of the trial Pr Odile Launay said; "This study should confirm the preclinical data and the ability of the vaccine candidate, based on the result of fundamental research conducted at the Pasteur Institute, to induce an immune response against HIV."

See Also:

Theravectys regulatory affairs and clinical trials in-charge Dr Emmanuelle Sabbah-Petrover said the company is planning to recruit the first patient by the end of December this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our early interactions with the French, Belgian and European regulatory agencies facilitated their investigations on our clinical trial applications," Sabbah-Petrover said.

Theravectys chief scientific officer Dr Cécile Bauche expects the clinical trials to demonstrate the safety and immunogenicity in humans within 12 months.

"This expected confirmation will not only bring tremendous hope for all HIV positive patients, but it will also open a path for new developments," Bauche said.